XML 37 R31.htm IDEA: XBRL DOCUMENT
v3.26.1

Agreements with Royalty Pharma - Schedule Represents Allocation of Transaction Consideration on a Relative Fair Value Basis to the Liability and the Common Stock (Detail) - USD ($) $ in Thousands | 3 Months Ended
--- | ---
Mar. 31, 2026 | Mar. 31, 2025
RP Aficamten Liability [Member] |  |
Royalty Liability [Line Items] |  |
Liabilities related to revenue participation right purchase agreements, net beginning balance | $ 320,764 | $ 262,599
Interest accretion | 18,816 | 14,037
Amortization of issuance costs | 0 | 0
Liabilities related to revenue participation right purchase agreements, net ending balance | 339,580 | 276,636
RPOM Liability [Member] |  |
Royalty Liability [Line Items] |  |
Liabilities related to revenue participation right purchase agreements, net beginning balance | 199,795 | 199,593
Interest accretion | 0 | 41
Amortization of issuance costs | 0 | 26
Liabilities related to revenue participation right purchase agreements, net ending balance | $ 199,795 | $ 199,660

X
- Definition Interest accretion. + References No definition available. + Details
Name: | cytk_InterestAccretion
Namespace Prefix: | cytk_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Liabilities related to revenue participation right purchase agreements, net. + References No definition available. + Details
Name: | cytk_LiabilitiesRelatedToRevenueParticipationRightPurchaseAgreementsNet
Namespace Prefix: | cytk_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Royalty liability. + References No definition available. + Details
Name: | cytk_RoyaltyLiabilityLineItems
Namespace Prefix: | cytk_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of amortization expense attributable to debt issuance costs. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details
Name: | us-gaap_AmortizationOfFinancingCosts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cytk_RoyaltyAgreementsTermsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_RoyaltyAgreementTermsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |